Natera, Inc. (NTRA) is a Healthcare stock trading at $231.43 (as of 2026-06-18), with a market capitalization of $31.99B and a trailing P/E of -139.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Natera provides molecular diagnostic testing services, including prenatal and pregnancy-related tests (such as non-invasive fetal screening and twin zygosity), screening for single-gene disorders and carrier status, and related genetic tests used in settings like in vitro fertilization and miscarriage evaluation, as well as gestational paternity testing. It also offers software and technology platforms for laboratories, including cloud-based access to its algorithms and bioinformatics, and circulating tumor DNA-based testing.